Acon Pharmaceuticals Inc United States

ACON Pharmaceuticals Inc. (ACON Pharma) is a specialty pharmaceutical company and focuses on siRNA and mRNA nanoparticle delivery, 505(b)(2) NDA, and complex ANDA drug product development with its captive drug delivery system and technology platforms. Acon Pharma is a privately held corporation located in Princeton, New Jersey, USA. As a dynamic pharmaceutical company in a vibrant life science research region, Acon Pharma leverages the expertise and experience of highly skilled, multi-disciplinary workforce to accelerate the product development of complex drug delivery systems. The Company’s key managers were primarily educated in US with advanced degrees and trained in the pharmaceutical industry for many years, and have possessed deep professional knowledge, technical know-how, and extensive experiences in pharmaceutical product development.

We are currently raising 5 million dollar fund to support IND-enabling studies for our patented liposomal siRNA for treatment of pulmonary fibrosis and long-acting microsphere for treatment of schizophrenia. We are also developing delayed release nanoemulsion for osteoporosis, and sustained release gel for fungal infection.
Company Size (Fulltime employees)
Year of foundation
2020
Please specify your partnering goal
Looking for investors and strategic partners
Headquartner in China
Assets Information 1
AP1302|siRNA Liposome Inhalation|pulmonary fibrosis|China, US
Assets Information 2
AP2602|Long-acting Microsphere Injection|schizophrenia, bipolar disease|China, US
Assets Information 3
AP6111|Self-emulsifying Nanoemulsion|osteoporosis|China, US
Biotech/Pharma Asset Stage
Xudong Yuan
CEO 
Functionality

Adragos Pharma Germany

Private equity firm
Company Size (Fulltime employees)
Please specify your partnering goal
Both raising further funds and driving deal pipeline
Headquartner in China
Mr. Andreas Raabe
Partner 
Functionality

Bayer Healthcare China

Bayer Healthcare
Dr. Min Pang
Alliance Manager 

Beijing Continent Pharmaceutical Co., Ltd. China

A private pharmaceutical company,headquartered in Beijing,focus on the research, development,manufacture and marketing of drug products for the treatment of organ fibrosis diseases and other related diseases.

Qin Li
Associate Director,Business Development 

BIOS Health United Kingdom

BIOS is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals. We have leveraged recent breakthroughs in AI and Machine Learning to translate the “language” of the nervous system for the first time. Being able to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is nothing short of a game-changer, holding the key to new treatments for conditions including heart disease and diabetes.

To find out more, contact us at partnerships@bios.health.

Company Size (Fulltime employees)
Year of foundation
2015
Partnering Objectives
Please specify your partnering goal
BIOS is currently raising venture capital from qualified investors. Please get in touch if you would like to participate.
Headquartner in China
Mr. Emil Hewage
Co-Founder, CEO 
Functionality

Buchang Pharma Group China

A pharmaceutical company
Website:
www.buchang.com
Company Size (Fulltime employees)
Please specify your partnering goal
licensing-in and partnership
Headquartner in China
Mr. Cliff Cheng
CSO 

Dao Tun GmbH Switzerland

Dao Tun is a consulting company, founded in 2019, specialised in cross-border collaboration between Europe and China, primarily in the healthcare and life science industry.
Dao Tun is based in the Basel region, one of the world's leading clusters for Pharma and Life Sciences and also part of the trinational Biovalley region (Switzerland, Germany, France).
Dao Tun team provides customised strategy and execution plan via in-depth interview and targeted research; quickly gains insights into the association and matching between potential partners to make accurate and effective connections; simplifies the processes, reduces the cost of communication, and establishes the trust with full care.
Dao Tun is a bridge builder who excels at understanding and interpreting their interests and needs, and aligning perspectives of different stakeholders and across cultures for win-win-win situation.

Dr. Tianke Wang
Dr. Tianke Wang
CEO 
Functionality

GCV Life India

Life science-focused Innovation licensing organizations looking to commercialize global innovations for the Indian and South Asian markets through a unique partnership-led model.
Dr. Chirag Jain
Analyst 
Functionality

Jiangsu Hengrui Medicine Co.,Ltd. China

Founded in 1970, Jiangsu Hengrui Medicine Co., Ltd. (JHM) is the largest publicly listed and a leading biopharma based in China with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, JHM has 6 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular therapeutic areas. Driven by internal R&D and global licensing and collaboration, JHM is committed to bring high quality products to patients.
Company Size (Fulltime employees)
Year of foundation
50 years
Partnering Objectives
Please specify your partnering goal
In-licensing clinical stage assets for China market; out-licensing ex-China rights of Hengrui assets
Headquartner in China
Assets Information 1
Please see the link below for our pipeline. Most of our assets are out-licensing candidates|https://www.hengruius.com/pipeline.html||China, US and global (please check with us for detailed info)
Ms. Linda Zhao
Head, US BD Team 
Functionality